Shares of 10x Genomics (NASDAQ:TXG - Get Free Report) shot up 5.8% during trading on Thursday. The company traded as high as $61.09 and last traded at $60.3820. Approximately 576,391 shares changed hands during trading, a decline of 81% from the average daily volume of 3,004,482 shares. The stock had previously closed at $57.07.
Analysts Set New Price Targets
Several research analysts recently weighed in on the stock. Argus started coverage on shares of 10x Genomics in a report on Monday, September 28th. They issued a "buy" rating and a $110.00 target price for the company. Royal Bank Of Canada began coverage on shares of 10x Genomics in a report on Tuesday, September 1st. They issued a "sector perform" rating and a $70.00 target price on the stock. Wall Street Zen raised shares of 10x Genomics from a "hold" rating to a "buy" rating in a report on Saturday, November 14th. Canaccord Genuity Group boosted their price objective on 10x Genomics from $60.00 to $100.00 and gave the stock a "buy" rating in a research note on Monday, October 12th. Finally, Morgan Stanley upped their price objective on 10x Genomics from $40.00 to $70.00 and gave the company an "equal weight" rating in a research report on Monday, October 12th. Five equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $68.40.
Check Out Our Latest Research Report on TXG
10x Genomics Trading Up 1.5%
The firm has a market cap of $7.62 billion, a P/E ratio of -111.43 and a beta of 2.03. The business has a 50-day moving average price of $73.38 and a 200-day moving average price of $43.10.
10x Genomics (NASDAQ:TXG - Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.12. 10x Genomics had a negative net margin of 10.84% and a negative return on equity of 8.19%. The company had revenue of $150.67 million during the quarter, compared to analyst estimates of $147.96 million. During the same period in the prior year, the firm earned ($0.22) earnings per share. The firm's revenue for the quarter was up 1.1% compared to the same quarter last year. On average, equities analysts anticipate that 10x Genomics will post -0.67 earnings per share for the current fiscal year.
Insider Buying and Selling
In other 10x Genomics news, CFO Adam Taich sold 46,388 shares of the firm's stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $64.57, for a total value of $2,995,273.16. Following the completion of the sale, the chief financial officer owned 316,344 shares of the company's stock, valued at approximately $20,426,332.08. This trade represents a 12.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Shehnaaz Suliman sold 5,723 shares of the business's stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of $81.19, for a total value of $464,650.37. Following the sale, the director owned 23,792 shares in the company, valued at $1,931,672.48. The trade was a 19.39% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 190,333 shares of company stock valued at $12,604,970 in the last 90 days. 8.84% of the stock is owned by insiders.
Institutional Trading of 10x Genomics
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quantinno Capital Management LP lifted its stake in shares of 10x Genomics by 16.0% in the 1st quarter. Quantinno Capital Management LP now owns 5,411,761 shares of the company's stock valued at $114,892,000 after purchasing an additional 744,558 shares during the period. Goldman Sachs Group Inc. increased its holdings in 10x Genomics by 8.1% in the third quarter. Goldman Sachs Group Inc. now owns 3,403,142 shares of the company's stock valued at $307,508,000 after buying an additional 254,283 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in 10x Genomics by 34.6% in the first quarter. Dimensional Fund Advisors LP now owns 2,042,950 shares of the company's stock valued at $43,357,000 after buying an additional 525,369 shares in the last quarter. First Trust Advisors LP raised its position in shares of 10x Genomics by 8.8% in the third quarter. First Trust Advisors LP now owns 451,226 shares of the company's stock worth $40,773,000 after acquiring an additional 36,332 shares during the period. Finally, Quantedge Capital Pte Ltd raised its position in shares of 10x Genomics by 104.2% in the first quarter. Quantedge Capital Pte Ltd now owns 416,553 shares of the company's stock worth $8,843,000 after acquiring an additional 212,600 shares during the period. Institutional investors and hedge funds own 84.68% of the company's stock.
About 10x Genomics
(
Get Free Report)
10x Genomics, Inc. develops technology for studying biological systems at single-cell and spatial resolution. Its instruments, consumables and software help researchers analyze gene expression and other features of cells while preserving information about their location within tissue. The company's product platforms include Chromium for single-cell analysis, Visium for spatial gene-expression analysis and Xenium for in situ analysis of gene activity within tissue samples. Its tools are used in areas such as immunology, neuroscience, cancer research and drug discovery.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider 10x Genomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 10x Genomics wasn't on the list.
While 10x Genomics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.